RedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018.

• jaimeuss_admin
• 17 בSeptember 2018
• Research
• 0 Comments

Continue Reading

RedHill Biopharma Ltd.: The Strategic Expansion and Clinical Progress are in line with the Company’s plans. Stock Target Price Unchanged.

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Energix Renewable Energies Ltd.: The revenues in H1 2017 attest the implementation of plans and expected growth in cash flows from projects. Target Price Unchanged.

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading